HoldsUp

DavidPerlmutterMD · 2025-01-06 · David Perlmutter (host), Georgia Ede

Revolutionizing Mental Health: The Rise of Metabolic Psychiatry | Dr. Georgia Ede

28 research-tied claims examined: 1 contradicted 6 overstated 3 context 16 supported 2 unverified

16

Supported by research

0:00:00Georgia Edesupportedvery low

In a published study of 31 psychiatric inpatients, 28 were able to stay on a ketogenic diet for 2 weeks or longer, all 28 improved substantially, 43% achieved full clinical remission from their primary psychiatric diagnosis, and 64% were discharged on reduced psychiatric medication.

"28 of those 31 patients were able to stay on the diet for 2 weeks or longer, which is what you need to do to start to see benefits. All 28 of those patients improved substantially to the point that 43% of them achieved full clinical remission from their primary psychiatric diagnosis and 64% of them left the hospital on less psychiatric medication" (said at 0:00:00)

The speaker accurately describes the published findings of a 2022 retrospective analysis (Danan et al., 2022, co-authored by Georgia Ede) evaluating 31 psychiatric inpatients placed on an adjunctive ketogenic diet. In that study, 28 of 31 patients adhered to the diet for more than 14 days, 100% (28/28) demonstrated clinical improvement, 43% (12/28) achieved clinical remission (defined by clinical rating scales or Clinical Global Impression scores), and 64% (18/28) were discharged on reduced psychiatric medication. Because this study is an uncontrolled, retrospective chart review, the certainty of evidence for the therapeutic efficacy of the ketogenic diet in this population is very low.

  • supports: The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatient… (Frontiers in psychiatry 2022) · cited 150x in the literature
    "In this retrospective analysis of clinical care, 31 adults with severe, persistent mental illness (major depressive disorder, bipolar disorder, and schizoaffective disorder) whose symptoms were poorly controlled despite intensive psychiatric management were admitted to a psychiatric hospital and placed on a ketogenic diet restricted to a maximum of 20 grams of carbohydrate per day as an adjunct to conventional inpatient care... Three patients were unable to adhere to the diet for >14 days and were excluded from the final analysis. Among included participants, means and standard deviations (SDs) improved for the Hamilton Depression Rating Scale scores from 25.4 (6.3) to 7.7 (4.2), P < 0.001 and the Montgomery-Åsberg Depression Rating Scale from 29.6 (7.8) to 10.1 (6.5), P < 0.001." (abstract, methods and results, passage verified)
    pubmedfull study (doi)
0:01:38David Perlmutter (host)supportedmoderate

Approximately one billion people worldwide currently suffer from mental illness.

"there are a billion people in the world right now suffering from mental illness" (said at 0:01:38)

Global epidemiological data from the Global Burden of Disease (GBD) Study support this figure. In the GBD 2023 analysis, an estimated 1.17 billion individuals (95% uncertainty interval: 1.06–1.31 billion) worldwide had a prevalent mental disorder, representing an age-standardized prevalence rate of roughly 14.2%. Previous GBD and World Health Organization estimates from 2019 similarly documented nearly one billion individuals (approximately 970 million) living with a mental disorder prior to further increases during subsequent years.

0:01:46David Perlmutter (host)supportedmoderate

Mental illness costs approximately $3 billion each day globally.

"it's costing us about $3 billion each and every day." (said at 0:01:46)

A daily global cost of approximately $3 billion translates to roughly $1.1 trillion per year. Global economic burden assessments by the World Health Organization and macroeconomic analyses by the World Economic Forum and Harvard School of Public Health show that mental health conditions cost the global economy around $1 trillion to $2.5 trillion annually (primarily driven by lost economic output, presenteeism, and absenteeism from common mental disorders like depression and anxiety), closely aligning with the $3 billion per day figure.

0:17:29Georgia Edesupportedhigh

The scientific hypothesis that depression is caused by deficient serotonin activity in the brain has largely been debunked.

"the science behind the serotonin hypothesis is extraordinarily thin to nonexistent. That serotonin—the idea that the reason why people develop depression is because they don't have enough serotonin activity in the brain—has largely been debunked." (said at 0:17:29)

A landmark systematic umbrella review evaluated the primary research areas examining the serotonin hypothesis of depression (including studies of serotonin and 5-HIAA metabolite levels, 5-HT1A receptor binding, SERT levels, tryptophan depletion, and SERT gene/gene-environment interactions). The review concluded that across all major research domains, there is no consistent evidence of an association between serotonin activity or concentration and depression, and no empirical support for the hypothesis that depression is caused by deficient serotonin activity.

0:28:29David Perlmutter (host)supportedmoderate

Selective serotonin reuptake inhibitors (SSRIs) exert anti-inflammatory effects and promote adult neurogenesis.

"there has been quite a bit of literature put out indicating that while there may not be an effect in terms of depression by the enhanced serotonin, that the SSRIs are actually to some degree anti-inflammatory, and that might explain why they have a modicum of efficacy. But in addition, one of the things seen in the laboratory is that for these antidepressants to work in rodents—and I don't know how they measure depression in rodents, I still don't get that, it's tough for me—is because they increase neurogenesis." (said at 0:28:29)

The speaker's assertions that SSRIs possess anti-inflammatory properties and that their behavioral efficacy in rodents depends on adult neurogenesis are well-supported by scientific literature. Systematic reviews and meta-analyses of clinical studies in patients with major depressive disorder demonstrate that SSRI monotherapy significantly decreases circulating levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1beta (IL-1β). In laboratory rodent models, landmark experimental studies demonstrate that chronic SSRI treatment stimulates adult hippocampal neurogenesis and that blocking this neurogenesis (such as through targeted hippocampal X-irradiation or genetic ablation) eliminates the behavioral responses to the antidepressants.

0:29:06David Perlmutter (host)supportedlow

Elevated levels of systemic inflammation reduce the rate of neurogenesis.

"Higher levels of inflammation reduce the growth of new brain cells, and that is obviously not good for cognitive function, but seems to have a role to play in depression as well." (said at 0:29:06)

Preclinical and in vitro human neural progenitor studies demonstrate that elevated systemic and central inflammation (driven by proinflammatory cytokines such as IL-1β, IL-6, and TNF-α) suppresses adult hippocampal neurogenesis by reducing neural progenitor proliferation, differentiation, and survival, as well as inhibiting synaptic integration. This inflammation-induced impairment in neurogenesis is strongly linked to deficits in learning, memory, and depressive-like behaviors in animal models. The certainty is graded as low because direct in vivo measurement of adult neurogenesis relies almost entirely on animal models and cultured human progenitor cells rather than direct observation in living humans.

0:30:45Georgia Edesupportedmoderate

When the brain develops insulin resistance, insulin has a harder time crossing into the brain.

"if the brain becomes insulin resistant, then insulin has a harder and harder time crossing into the brain." (said at 0:30:45)

Circulating insulin crosses the blood-brain barrier (BBB) via a saturable, receptor-mediated transport mechanism. In preclinical and clinical models of obesity, type 2 diabetes, and central nervous system (CNS) insulin resistance (frequently observed in Alzheimer's disease), insulin transport across the BBB is significantly reduced and impaired. Central insulin signaling and insulin receptor function have also been shown to directly regulate the rate of BBB insulin influx, confirming that insulin resistance in the CNS and BBB endothelial cells diminishes the brain's uptake of peripheral insulin.

0:33:00David Perlmutter (host)supportedlow

In early Alzheimer's disease, there is more glucose present in the brain than in control groups, but the brain is unable to use it.

"In fact, in the early Alzheimer situation, there is more glucose than in the control group, more glucose is just not being able to be used." (said at 0:33:00)

Post-mortem human brain tissue analyses have shown that brain tissue glucose concentrations are elevated in individuals with Alzheimer's disease pathology compared to cognitively normal controls, co-occurring with impaired glycolytic flux (reduced ratios of glycolytic end-products) and downregulation of neuronal glucose transporters (GLUT3). This reflects impaired glucose utilization and dysregulation rather than a deficiency of brain glucose availability.

0:33:13David Perlmutter (host)supportedmoderate

Metabolic issues in cerebral glucose utilization can be detected on fluorodeoxyglucose PET scans 20 years before clinical memory loss appears.

"It's a metabolic issue that's happening early that can be determined and fingerprinted on PET scans, fluorodeoxyglucose utilization PET scans of the brain 20 years, i.e., in your 30s and 40s, before you suddenly can't remember grandchildren's names" (said at 0:33:13)

Research demonstrates that regional reductions in cerebral glucose utilization can be detected using fluorodeoxyglucose positron emission tomography (FDG-PET) in young adults (ages 20–39) decades before clinical memory loss or dementia symptoms typically appear. In group-level comparisons, cognitively normal young adults carrying the apolipoprotein E (APOE) ε4 susceptibility gene exhibited abnormally low glucose metabolic rates in the same brain regions (posterior cingulate, parietal, temporal, and prefrontal cortex) that are characteristically impaired in Alzheimer's disease. However, these findings represent statistical group differences in genetically at-risk individuals rather than a validated individual screening test for the general population.

0:40:39Georgia Edesupportedmoderate

Experiments by Stephen Cunnane and others show that when brain cells are given both glucose and ketones, they choose to burn a mixture of the two.

"experiments by Dr. Cunnane and others have shown this: that if you take a brain cell and you give it all the glucose it could ever want, but you also give it ketones, it will choose to burn a mixture of the two" (said at 0:40:39)

Dual-tracer positron emission tomography (PET) research led by Stephen Cunnane and colleagues in healthy humans and clinical populations demonstrates that the brain utilizes both glucose and ketone bodies simultaneously when ketones are available. In clinical PET studies measuring cerebral metabolic rates with 11C-acetoacetate and 18F-fluorodeoxyglucose, brain ketone uptake increases in direct proportion to circulating plasma ketone levels, operating alongside ongoing glucose metabolism and providing a dual-fuel energy mixture rather than relying exclusively on a single fuel source.

0:44:52Georgia Edesupportedvery low

In a 2022 published study by Dr. Albert Danan and co-authors on 31 treatment-resistant psychiatric inpatients, 28 stayed on a ketogenic diet for 2 weeks or longer, 43% achieved full clinical remission, and 64% were discharged on less psychiatric medication.

"So this study, which I was a co-author on—this study was published in 2022. The clinical work was done by my friend and colleague Dr. Albert Danan, who is a psychiatrist who's been practicing psychiatry in Toulouse, France for more than 35 years now. And he invited 31 of his most treatment-resistant patients with major depression, bipolar disorder, and schizophrenia to come into the hospital and try a mildly ketogenic whole-foods diet under his supervision to see whether or not it would be helpful... 28 of those 31 patients were able to stay on the diet for two weeks or longer... 43% of them achieved full clinical remission from their primary psychiatric diagnosis and 64% of them left the hospital on less psychiatric medication." (said at 0:44:52)

The speaker accurately describes the findings of the 2022 retrospective study by Danan et al. (co-authored by Georgia Ede), published in Frontiers in Psychiatry. In that analysis of 31 hospitalized adults with treatment-resistant major depression, bipolar disorder, or schizoaffective disorder, 28 patients adhered to a carbohydrate-restricted ketogenic diet for at least 14 days. Among those 28 patients, 43% (12/28) achieved clinical remission (defined by clinical rating scales) and 64% (18/28) were discharged on reduced psychiatric medication dosages. Because this was an uncontrolled, retrospective chart review of clinical care rather than a randomized controlled trial, the certainty of evidence for clinical efficacy is very low.

0:55:20Georgia Edesupportedmoderate

Postprandial glucose spikes are among the earliest indicators of metabolic dysfunction before fasting glucose rises.

"And so if you're getting these peaks after meals, that's really one of the first clues to metabolic dysfunction or to the clue that you're eating the wrong way. It'll all come back down to normal by the next morning until you've got type 2 diabetes." (said at 0:55:20)

Established metabolic research shows that postprandial hyperglycemia (impaired glucose tolerance) is one of the earliest measurable dysfunctions in the progression toward type 2 diabetes, typically developing years before fasting plasma glucose becomes abnormal. In impaired glucose tolerance, loss of early-phase insulin secretion causes elevated postprandial glucose excursions while basal hepatic glucose output and fasting plasma glucose remain normal or near normal.

0:30:26Georgia Edesupportedmoderate

The vast majority of Americans currently have at least some degree of insulin resistance.

"now the vast majority of Americans have at least now some degree of insulin resistance" (said at 0:30:26)

Nationally representative epidemiological data from the National Health and Nutrition Examination Survey (NHANES) support the claim. An analysis of NHANES 2009–2016 data (Araújo et al., 2019, PMID: 30484738) found that only 12.2% of US adults met all criteria for optimal cardiometabolic health (which includes normal glucose, blood pressure, lipid profiles, and waist circumference without medication), meaning approximately 88% of American adults have at least one cardiometabolic abnormality linked to insulin resistance. Furthermore, when evaluating insulin resistance and dysglycemia broadly (including metabolic syndrome, prediabetes, and type 2 diabetes), the majority of American adults exhibit markers of impaired metabolic health.

0:37:05David Perlmutter (host)supportedmoderate

Fructose intake triggers physiological fat synthesis through uric acid signaling pathways.

"trigger our physiology to make more fat via the fructose and uric acid, and we would survive." (said at 0:37:05)

Mechanistic, preclinical, and human observational/narrative review studies support the host's claim that fructose intake stimulates fat accumulation (de novo lipogenesis and triglyceride accumulation) via intracellular purine degradation and uric acid generation. Rapid fructose phosphorylation consumes ATP, causing AMP degradation to uric acid, which generates mitochondrial oxidative stress and triggers lipogenic signaling pathways. Historically/evolutionarily, this pathway function acted as an adaptive survival mechanism to store fat and glycogen during periods of nutrient or water scarcity.

0:55:03Georgia Edesupportedhigh

Hemoglobin A1C reflects an individual's average blood sugar levels over the preceding three months.

"The hemoglobin A1C is a reflection of your average blood sugar over the past three months." (said at 0:55:03)

Hemoglobin A1c (HbA1c) is a well-established clinical biomarker that reflects an individual's average blood glucose exposure over the preceding 2 to 3 months (approximately 120 days, corresponding to the average lifespan of human red blood cells).

1:00:50David Perlmutter (host)supportedhigh

The gut microbiome functions to support and maintain the integrity of the intestinal epithelial barrier (gut lining).

"because of how we've threatened our microbiome that should be shoring up the integrity of the gut lining, and therefore we can't tolerate exactly those foods that we theoretically should have" (said at 1:00:50)

Extensive scientific literature, including systematic reviews and mechanistic studies, establishes that the gut microbiome and its microbial metabolites (such as short-chain fatty acids like butyrate) play a fundamental role in maintaining and supporting the integrity of the intestinal epithelial barrier. Commensal microbes regulate epithelial tight junction proteins, preserve the protective mucus layer, and modulate immune responses to maintain mucosal barrier function.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.